# Analogous humoral antigen recognition 1 between Monkeypox-infected and Smallpox-2 vaccinated individuals 3

6 Ashley D. Otter<sup>1\*†</sup>, Scott Jones<sup>1\*</sup>, Bethany Hicks<sup>1\*</sup>, Daniel Bailey<sup>2</sup>, Helen Callaby<sup>2</sup>, Catherine 7 Houlihan<sup>2</sup>, Tommy Rampling<sup>2</sup>, Nicola Claire Gordon<sup>2</sup>, Hannah Selman<sup>1</sup>, Panayampalli S. 8 Satheshkumar<sup>3</sup>, Michael Townsend<sup>3</sup>, Ravi Mehta<sup>4</sup>, Marcus Pond<sup>5</sup>, Rachael Jones<sup>5</sup>, Deborah 9 Wright<sup>6</sup>, Clarissa Oeser<sup>7</sup>, Simon Tonge<sup>8</sup>, Ezra Linley<sup>8</sup>, Georgia Hemingway1, Tom Coleman<sup>1</sup>, 10 Sebastian Millward<sup>1</sup>, Aaron Lloyd<sup>1</sup>, Inger Damon<sup>3</sup>, Tim Brooks<sup>2</sup>, Richard Vipond<sup>6</sup>, Cathy 11 Rowe<sup>1</sup>, Bassam Hallis<sup>6</sup> 12 13

- 14
- 15
- 16 \* -contributed equally
- 17 + - corresponding author: ashley.otter@ukhsa.gov.uk
- 18
- 19
- 20
- 21 1 - Emerging Pathogen Serology group, UKHSA Porton Down, Wiltshire, UK
- 22 2 - Rare and Imported Pathogens Laboratory, UKHSA Porton Down, Wiltshire, UK
- 3 Poxvirus and Rabies Branch, Centre for Disease Control and Prevention, Atlanta, Georgia, USA 23
- 24 4 – Imperial College Health Trust, London, UK
- 25 5 - Chelsea and Westminster Health Trust, London, UK
- 26 6 - Research and Development, UKHSA Porton Down, Wiltshire, UK
- 7 Immunisation and Vaccine Preventable Diseases Division, UKHSA Colindale, London, UK 27
- 28 8 – Seroepidemiology Unit, UKHSA Manchester, Manchester, UK
- 29
- 30

# 31 Abstract

In early 2022, a cluster of Monkeypox (now termed MPOX) virus (MPXV) cases were identified within the UK with no prior travel history to MPXV-endemic regions, suggesting localised transmission of MPXV within the UK. Subsequently, cases were identified in several other non-endemic countries and currently exceed 80,000 worldwide, primarily affecting gay, bisexual, and other men who have sex with men. Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals to provide protection and limit the spread of MPXV.

We have developed a comprehensive array of ELISA assays to study poxvirus-induced 39 antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of 40 serum samples from individuals with one, two, or three doses of IMVANEX or ACAM2000 41 (Modified Vaccinia Ankara (MVA)) vaccination, and those with prior MPOX infection were 42 43 tested against these antigens, with Pearson correlation, principal component analysis and receiver operator curve statistics used to further elucidate antigenic responses to pox-virus 44 45 infection. Furthermore, using our data, we demonstrated the development of a pooled antigen ELISA that can reliably detect antibody responses induced by Smallpox vaccination or MPXV 46 47 infection.

Using diverse poxvirus antigen ELISAs, we observe that one dose of Smallpox vaccination 48 induces a low number of antibodies, primarily against MPXV B2, with a second dose inducing 49 considerably higher antibody responses against B2R but also to other MPXV antigens such 50 51 as B5, E8, M1, and A35. Prior MPXV infection, both Clades IIa and IIb, induce variable responses, but similarly induce antibody responses to poxvirus antigens observed in 52 Smallpox-vaccinated individuals, and additionally responses to MPXV A27, A29 and H3. 53 54 Principal component and Pearson correlation matrix identified MPXV A27 as a differential 55 between IMVANEX and MPOX-infected individuals, whilst MPXV M1 (VACV L1) is likely a serological marker of IMVANEX-vaccination. When using recombinant MPXV/VACV protein 56 57 homologues, we also observe a difference in antigen binding, with variability based on the 58 individual's originating infection/vaccination. Using a pooled-antigen ELISA, we also demonstrate a sensitivity of 97.14% (95% CI:91.93-99.22) and specificity of 98.23% (96.67-59 99.07) in detecting poxvirus antibodies with applicability to measuring longitudinal antibody 60 responses post-vaccination/post-MPXV infection. 61

Here, we show that both MPXV-infected or Smallpox-vaccinated individuals mount antibodies
able to bind a diverse but core set of poxvirus antigens, with implications for future vaccine
(e.g., mRNA-based) and therapeutic (e.g., monoclonal antibodies) targets. We identify low
levels of antibodies observed in those post dose one IMVANEX, but considerably higher levels

- 66 of antibodies post dose two. We also demonstrate that homologous VACV and MPXV antigens
- 67 may offer a mechanism for discriminating between vaccinated and MPXV-infected individuals
- 68 through differential binding, aiding in serosurveillance and future immunology studies.

#### 69 Introduction

## 70

MPOX virus (MPXV), is a member of the Orthopoxviruses, a group of closely related viruses, 71 72 some of which are highly pathogenic that cause distinctive diseases in humans and animals<sup>1–</sup> <sup>5</sup>. Within the Orthopoxvirus genus, other members of this viral family include Vaccinia virus 73 (VACV), the foundation of a number of Smallpox vaccinations; Variola virus (VARV), the 74 causative virus of Smallpox disease which was subsequently declared eradicated in 1980<sup>3,6</sup>; 75 76 and Cowpox virus (CPXV), the virus likely used by Edward Jenner to inoculate individuals against Smallpox<sup>2,7</sup>. Whilst Orthopoxviruses share a high degree of genetic homology<sup>2,8</sup>, they 77 vary in their pathogenicity to humans. VARV is highly pathogenic in humans, contributing to 78 79 300-500 million historic deaths worldwide, with no known animal reservoir, aiding in its eradication. VACV can cause disease in humans<sup>9,10</sup>, however attenuated strains of VACV 80 have been developed through serial passage, as the basis of a number of licensed vaccines 81 against Smallpox – Dryvax®®, ACAM2000 (both based on the New York City Board of Health 82 vaccinia virus strain) and Modified Vaccinia Ankara (MVA) Bavarian Nordic (MVA-BN); trade-83 84 names 'IMVANEX' and 'JYNNEOS).

After the eradication of Smallpox in 1980<sup>6</sup>, routine Smallpox vaccination, using Vaccinia virus, 85 was halted worldwide<sup>3,11</sup>. Since this vaccination programme stopped, it has been suggested 86 that the worldwide population remain increasingly at risk of poxvirus infection, due to waning 87 antibodies in those with prior Smallpox vaccination and a lack of vaccine-derived immunity in 88 those born after 1980<sup>11,12</sup>. 89

MPXV is a zoonotic pathogen (with a presumed rodent animal reservoir) causing MPOX 90 disease<sup>1,13,14</sup>. Previously, it has been identified only in central and Western African countries 91 with occasional importations in returning travellers. There have been a small number of 92 onward transmissions in some countries such as the UK<sup>15–17</sup> and USA<sup>18–20</sup>, however minimal 93 mutations are observed between isolates spanning multiple years<sup>2</sup>. 94

In the UK on the 7th of May 2022, one case of MPXV was identified in a returning traveller 95 from Nigeria. A week later, an autochthonous familial cluster was identified, with no link to the 96 earlier case and no travel history outside of the UK to MPXV-endemic regions<sup>21,22</sup>. Shortly 97 98 afterwards, further MPXV cases were identified in the UK, largely in gay, bisexual, and other men who have sex with men (GBMSM) with no travel to endemic countries or known exposure 99 to confirmed cases. Thereafter, other non-endemic countries including the USA, Spain, 100 Germany, Portugal and France also identified similar cases and evidence emerged of local 101 transmission in these countries<sup>21</sup>. To date, >80,000 cases of MPXV have been identified 102 alobally<sup>23</sup>, the majority of which have been in GBMSM<sup>22</sup>. Whole genome sequencing has 103

identified 30-80 mutations in sequences from MPXV isolated during the current outbreak,
which has been termed Clade IIb, compared to previous MPXV cases from Clade I or Clade
Ila<sup>24-26</sup>. Mutations within Clade IIb were primarily either GA- to AA-, or TC- to TT substitutions,
suggesting that host factors such as APOBEC3 cytosine modification led to these mutations,
possibly due to sustained infection in a new host or altered phenotypic/transmission
methods<sup>25,26</sup>.

To limit transmission during the 2022 MPXV outbreak, public health agencies recommend 110 Smallpox vaccination, as previous studies have shown protection from MPOX disease using 111 the Smallpox vaccines such as IMVANEX or ACAM2000<sup>27-31</sup>. The immunology of Dryvax®, 112 ACAM2000 and IMVANEX vaccines has been well studied<sup>27,32–36</sup>, with antibody responses 113 detected up to 35 years post-Smallpox vaccination<sup>34</sup>. However, studying the immunology to 114 MPXV infection and disease has been limited by the geographical distribution, limited number 115 of human cases worldwide and access to convalescent serum samples. Animal models have 116 been undertaken to understand immunology from MPOX disease in species such as 117 macagues<sup>28,31</sup> and prairie dogs<sup>27</sup>, however, the translation of this to human MPOX infections 118 119 is unknown.

Whilst T-cell immune responses to MPOX infection have been studied during the current Clade IIb 2022 outbreak<sup>37,38</sup> and previous oubreaks<sup>39</sup>, we sought to determine the humoral response and antigen recognition induced by both Clade IIa and IIb MPXV infection, with comparisons to IMVANEX and ACAM2000 vaccinated individuals. Similarly, using a combination of data, we demonstrate the ability of a multi-antigen ELISA to study antibody responses in Smallpox-vaccinated or MPOX-infected individuals.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# 127 Materials and methods

128

# 129 Serum samples from Smallpox vaccinated individuals

Individuals with prior or imminent IMVANEX vaccination were recruited from UKHSA Porton 130 131 Down. Written informed consent was given by each participant prior to sampling. Individuals in the process of receiving IMVANEX vaccination were bled before their primary intramuscular 132 vaccination (n=18), then further bled at 24 days post dose one (n=8) and 14 (n=10), 43 (n=7), 133 63 (n=8) and 84 days (n=7) post dose two. Two individuals with historical IMVANEX 134 vaccination (>4 years prior) receiving a booster were bled 14 days post dose (n=2). In addition, 135 serum samples were provided by the Poxvirus and Rabies Branch at the US Centre for 136 137 Disease Control and Prevention (US-CDC) from individuals post ACAM2000 single dose 138 vaccination (n=4) and multiple dose vaccination (n=1). Further detail can be found in **Table 1**. 139

# 140 MPOX Convalescent serum

Residual and anonymised MPOX convalescent serum from PCR-confirmed cases from the 141 142 2022 Clade IIb outbreak (n=43) were obtained for diagnostic assay development from the 143 Rare and Imported Pathogens Laboratory, Imperial College Healthcare NHS Trust, and 144 Chelsea and Westminster Hospital NHS Foundation Trust. Date of birth was used a proxy for historic Smallpox vaccination (<1971), although noted that not all patients born prior to the 145 end of the eradication programme may have been vaccinated. Days since diagnosis was also 146 recorded. Convalescent MPOX Clade IIa sera from 2018 and 2019 (n=3) were obtained from 147 148 the Rare and Imported Pathogens Laboratory from previous imported MPOX cases.

149

# 150 Negative and confounder samples

151 To determine pox-antigen reactivity and background pox-antibody reactivity, paediatric serum

- samples were sourced from the UKHSA Seroepidemiology Unit (SEU), Manchester (n=256).
- In addition, confounder serum samples from those with PCR-confirmed infection with CMV
   (n=99), EBV (n=100) and VZV (n=100) along with serum samples positive for Rheumatoid
- 155 factor (n=100) were used to determine assay specificity.
- 156

# 157 Antigens

Recombinant MPX protein antigens were sourced from several commercial companies, as either Eukaryotic- or Prokaryotic- expressed proteins (**Table 2** and supplementary table 1) as follows: A14, A26, A27, A29, A36, A44, B5, B6, C15, C18, D13, D14, E8, F3 and L1 (ProteoGenix, France), B2 and C19 (Abbexa, UK), A5L and L4R/VP8 (Native Antigen Company, UK) and A33, A35, H3, I1 and M1 (SinoBiological, China). MPXV sequences for recombinant protein expression were all based on Clade II.

Additionally, recombinant VACV Copenhagen protein antigens A27, A33 and B5 were sourced

165 from SinoBiological.

# 166 Single antigen ELISAs

ELISAs utilising single MPXV or VACV antigens were all performed using the same method. 167 with variation in the coating antigen only. Briefly, 48 wells of a Corning High-Binding 96-well 168 plate were coated with 100 µl/well of 0.1 ug/ml recombinant antigen overnight at 4°C, with the 169 other 48 wells 'coated' with PBS (Gibco, 10010). After overnight incubation, plates were 170 washed three times with 300 µl/well of PBS with Tween20 (0.01% final) using a Biotek 405 TS 171 plate washer before being blocked with 200 µl SuperBlock (ThermoFisher, 37516) for 60 172 173 minutes at room temperature. Plates were washed again as before, serum samples were 174 diluted to 1:200 in Superblock and 100 µl per well was applied to both the antigen-coated and PBS-only wells. After a 60-minute incubation with the samples at 37°C, plates were washed 175 as before and 100 µl/well goat anti-human IgG preabsorbed H+L (AbCam, ab98624), diluted 176 1:8000 in Superblock, was added to the plate. Plates were incubated for a further 60 minutes 177 at 37°C, followed by a wash with 300 µl/well of PBS with 0.01% Tween20 five times. Plates 178 were then developed with 50 µl/well 1-Step™ Ultra TMB-ELISA Substrate Solution 179 (ThermoFisher, 34029) for 30 minutes at 37°C and stopped with 50 µl/well KPL TMB Stop 180 Solution (Seracare, 5150-0021). Plates were then read at an absorbance of 450nm using a 181 Infinite F50 plate reader (Tecan, 30190077). 182

183

# 184 Pooled antigen ELISA

A pooled-antigen ELISA was performed similarly to single antigen ELISAs described above,
however, wells were coated with 100 µl/well of a pool of recombinant MPXV antigens A35, B2,
B6 and E8, and recombinant VACV antigen B5, each at a concentration of 0.1 ug/ml. In
addition, to determine endpoint titres, samples were also serially diluted 1:4 seven times in
SuperBlock, starting at a 1:100 dilution and 100 µl added per well.

190

# 191 Data Analysis

Before analysis, the absorbances achieved on the PBS-only wells were subtracted from the corresponding absorbances achieved on the antigen-coated wells.

All data analysis (curve fitting, receiver operator curve, Pearson correlation or principal component analysis) was performed using GraphPad Prism 9.2.0 (GraphPad Software, USA) unless otherwise stated. For Pearson correlation, analysis was performed whereby *r* was computed for every pair of *y* data set and used to generate a correlation matrix. Data were assumed to have Gaussian distribution with *p*-values determined using the Two-tailed method. Principal component analysis was performed using the OD of each antigen for each sample

- as a continuous variable and principal components were selected based on parallel analysis
- with 1,000 simulations performed at a 95% percentile level. The results of the principal
- 202 component analysis were grouped by sample group.
- 203 The endpoint titres of a sample were calculated by fitting a sigmoidal 4PL model to sample
- absorbances versus log<sup>10</sup> transformed sample dilution and interpolating the dilution at an
- absorbance of 0.1926.

### Table 1: Overview of samples used in this study. 206

	Sample Group	n-	Median time since	Range since	Median			
	Sample Group	11=	vax/inf (Days)	vax/inf (Days)	age			
	IMVANEX pre-vaccination		-	-	27			
Negatives	ACAM2000 Pre-vaccination	5	-	-	N/A			
	Paediatric negatives	256	-	-	3			
	IMVANEX post-dose 1 (time point 1)	8	24	14	26			
Smallpox vaccinated	IMVANEX post-dose 2 (time point 1)	10	14	14-28	27			
	IMVANEX post-dose 2 (time point 2)	7	43	37-63	26			
	IMVANEX post-dose 2 (time point 3)	8	63	63-85	26			
	IMVANEX post-dose 2 (time point 4)	7	84	84-106	26			
	ACAM2000 vaccinated	5	40	30-200-	23			
MPOY	Convalescent MPOX (Clade IIa)	3	7	5-20	37			
	Convalescent MPOX (Clade IIb)	43	81	20-113	37			
	Confounder: CMV (aged ≤50)	62			34			
	Confounder: CMV (aged ≥51)	37		63				
	Confounder: EBV (aged ≤50)	54			25			
$\frac{\text{MPOX}}{\text{Convalescent MPOX (Clade IIa)}} = \frac{3}{3}$ $\frac{\text{Convalescent MPOX (Clade IIb)}}{\text{Convalescent MPOX (Clade IIb)}} = \frac{3}{3}$ $\frac{3}{3}$ $\frac{1}{3}$ $\frac{3}{3}$ $\frac{3}{3}$ $\frac{3}{3}$ $\frac{3}{3}$ $\frac{1}{3}$ $\frac{3}{3}$ $\frac{3}{3}$ $\frac{1}{3}$ $\frac{3}{3}$ $\frac{3}{$	Ν/Δ	NI/A	62					
	Confounder: Rheumatoid (aged ≤50)	82	11/7	N/A	15			
	Confounder: Rheumatoid (aged ≥51)	18						
	Confounder: VZV (aged ≤50)	58			32			
	Confounder: VZV (aged ≥51)	42			60			

209 
**Table 2:** MPXV antigens and their homologues in VACV and known or predicted functions.

Antigens in bold are recombinant antigens used in this study. <sup>1</sup> MPXV proteins labelled 210

according to the genome of MPXV virus Zaire-96-I-16 (NC\_003310). <sup>2</sup> VACV proteins 211

labelled according to VACV Copenhagen (M35027). Data obtained from<sup>40-44</sup> 212

MPXV Protein <sup>1</sup>	VACV Protein <sup>2</sup>	VACV vs MPXV homology (%)	Туре	Protein description/function				
A5	A4	95.0	Late	39-kDa immunodominant virion core protein				
A14	A13	92.8	Late	IMV inner and outer membrane protein				
A26	-	N/A	Late	Similar to cowpox A-type inclusion protein				
A27	-	N/A	Late	N-terminal of A-type inclusion body protein of CPV, missing from MVA Bavarian Nordic (IMVANEX) strain				
A29	A27	93.6	Late	Intracellular mature virus (IMV) surface membrane 14- kDa fusion protein, binds cell surface heparan				
A33	A31	86.6	-	Unknown function, 53 bp insertion in MPXV C-terminus				
A35	A33	96.1	Late	Extracellular enveloped virus (EEV) envelope glycoprotein, needed for formation of actin-containing microvilli and cell-to-cell spread				
A36	A34	95.2	Late	EEV envelope glycoprotein, lectin-like, required for infectivity of EEV, formation of actin-containing microvilli, and cell-to-cell spread				
A44	-	N/A	-	Unknown function, gene not predicted to be present in VACV Copenhagen, ACAM2000 or IMVANEX strains				
B2	A56	93.0	Early-Late	EEV Type I membrane glycoprotein hemagglutinin, prevents cell fusion				
B5	B4	93.1	-	Ankyrin-like				
B6	В5	95.9	Early-Late	Palmitated 42-kDa EEV glycoprotein required for efficient cell spread and found on membrane of infected cells and EEV envelope, complement control protein-like				
C15	F9	99.1	Late	MV membrane protein – required for virus entry				
C18	F12	97.2	Early-Late	IEV, actin tail formation				
C19	F13	98.7	Late	Major envelope antigen of EEV, wrapping of IMV to form IEV, phospholipase D-like				
D13	C4	94.3	Early	Intracellular protein – inhibits NF-κB activation				
D14	C3	93.1	Early	Secreted complement binding protein				
E8	D8	94.7	Late	IMV surface membrane 32 kDa protein, binds cell surface chondroitin sulfate, IMV adsorption to cell surface				
F3	E3	86.3	Early	IFN resistance, dsRNA binding, inhibits dsRNA dependent protein kinase, and 2-5A-synthetase				
H3	НЗ	93.2	Late	IMV heparan-binding surface membrane protein				
l1	l1	99.4	Late	Virosomal protein essential for virus multiplication				
L1	J1	96.7	Late	IMV membrane protein – participates in virion morphogenesis				
L4	J4	100	Early	RNA pol 22-kDa subunit				
M1	L1	98.8	Late	Myristylated IMV surface membrane protein				

## 214 Results

215

# Antigen recognition is analogous between Smallpox-vaccinated and Monkeypox convalescent individuals

In total 27 pox-virus antigens (24 MPXV and 3 VACV antigens), spanning diverse functions from structural viral proteins to those involved in virion morphogenesis and host immunomodulation (**Table 2**) were tested against a panel of serum samples of those with prior smallpox-vaccination or MPOX infection (**Figure 1**).

222

223 Of the negative samples, individuals demonstrated minimal antibody binding to all the MPXV 224 or VACV antigens, with the exception of one individual, showing binding to the MPXV H3 and 225 VACV A27 antigen. Binding to MPXV C18 was observed across all negative samples. In 226 individuals that received one dose of the IMVANEX vaccine, antibody binding to MPXV and VACV antigens was generally low (post-dose 1 (PD1), Figure 1), however, all individuals 227 228 generated antibodies post-vaccination that were able to bind the MPXV B2 (VACV A56) 229 antigen. Antibody binding to the VACV B5 and the MPXV homologue; B6, was variable across 230 individuals, only one individual demonstrated robust antibody binding to both the VACV-B5 and MPXV-B6 antigens. 231

232

Two-dose IMVANEX vaccinated individuals (14-days post-vaccination) demonstrated diverse 233 234 recognition of a number of MPXV and VACV antigens, with the strongest binding of antibodies 235 observed to VACV B5 and MPXV B6, followed by MPXV antigens A35, B2, E8 and M1 (Postdose 2, time point 1 (PD2.1), Figure 1). Some individuals had antibodies able to bind MPXV 236 237 A5, A29 and H3, but absorbances were generally low, with the exception of MPXV A29 in 238 which two individuals demonstrated strong binding. Following further time points, post-dose 2 239 vaccination (43-, 63- and 84-days post-dose 2), lower binding to antigens was observed, in 240 particular to MPXV antigens B2, A35, B6, E8 and M1, and VACV A33 and B5 demonstrating similar decreasing binding. 241

242

We were also able to sample two individuals that received two historical IMVANEX doses (>3 243 244 years prior) with a booster (third) dose of IMVANEX (Post-dose 3 (PD3), Figure 1). These individuals show similar antibody binding to antigens as those in the post-dose 2 cohort, with 245 strong antibody binding to the MPXV B6, E8, A35, H3 and M1 antigens, and the VACV A33 246 and B5 antigens. ACAM2000 Smallpox vaccination similarly induced antibodies that could 247 bind the same antigens as IMVANEX-vaccinated individuals, with the exception of the MPXV 248 M1 antigen, whilst binding was observed to the MPXV A27 antigen, which was not observed 249 in IMVANEX-vaccinated individuals. 250

## 251

252 Serum samples from individuals with prior MPOX infection were similar to those from post-253 vaccination individuals, primarily mounting antibodies that bind VACV B5, A27 and A33 and MPXV-B2, B6, A27, A35 and E8, with variable binding across different individuals to these 254 antigens and others such as A5, A14, A29, M1 and H3 (Figure 1). Serum samples from 255 individuals with confirmed MPOX disease prior to the 2022 outbreak (Clade IIa) displayed 256 similar antibody binding to the same antigens as serum samples from individuals during the 257 2022 outbreak (Clade IIb), notably A35, A27, B2 and B6, and VACV-B5, but variable binding 258 to MPXV-A29 and A44. Notably, no difference in antigen recognition was observed between 259 those aged <51 and >51, with the latter more likely to have had historical smallpox vaccination 260 (Supplementary Figure 1). 261

262

263 Using Pearson correlation, trends in antibody binding to diverse MPXV and VACV antigens 264 were determined (Figure 2). C18 was removed from the correlation analysis, as non-specific antibody binding was observed. Most negative samples correlated either strongly with one 265 another or with minimal correlation, with some samples demonstrating poor correlation to other 266 267 negative samples. Furthermore, minimal correlation of antibody binding was observed between negative serum samples and serum samples obtained from those post Smallpox 268 vaccination and post-MPOX infection, with the exception of dose-one IMVANEX vaccinated 269 270 individuals, who demonstrated variable correlation in antibody binding to those post ACAM2000 vaccination, post-dose 2 IMVANEX vaccination or post-MPOX infection. 271

272

Conversely, serum samples from those post two dose IMVANEX vaccination at four different 273 time points (14-, 43-, 63- and 84-days) had the strongest positive correlation observed, both 274 between individuals and over different time points, with decreasing correlation over time since 275 276 second-vaccine dose (Figure 2). Serum from post two dose IMVANEX vaccinated also strongly and positively correlated with ACAM2000 vaccinated individuals and convalescent 277 Clade IIa and IIb MPOX infection, again with similar, strong correlation to one another. MPOX-278 279 infected individuals were highly correlated to one another, but as described earlier, also 280 strongly correlated with those post-Smallpox vaccinations. A negative correlation was observed between the negative samples and those ACAM2000 vaccinated, two-doses of 281 IMVANEX, or MPOX-infected individuals. Significance of individual samples to one another 282 using Pearson correlation can be found in **Supplementary Figure 2**. 283

- 284
- 285



Figure 1: Heatmap of ELISA results of serum samples from negative, vaccinated (IMVANEX or ACAM2000) or MPXV-infected individuals using individual MPXV or VACV recombinant antigens. Colour scale represents the OD. **Top panel**) MPX antigens, split according to the different sample groups. **Middle panel**) VACV antigens, split according to the different sample groups. **Bottom panel**) Using a pool of four MPXV and one VACV recombinant antigens.

291

292

293

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



1.0 0.5 0 -0.5 -1.0

294

**Figure 2:** Pearson correlation matrix of VACV and MPXV antigens in groups with no prior infection or smallpox vaccination (negatives), IMVANEX vaccinated, ACAM2000 vaccinated and convalescent MPXV-infected individuals. Correlation was performed using all MPXV/VACV antigens, with the exception of C18. PD: IMVANEX post-dose, 2.1; 14 days, 2.2; 43 days, 2.3 63 days and 2.4; 84 days.

300

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 302 **Correlation is observed between antibody binding to MPXV and VACV homologous**

- Similarly, Pearson correlation was used again to determine the correlation between
   MPXV/VACV antigens across the different groups (Figure 3A-C, Supplementary Figure 4).
   MPXV and VACV protein homologues were strongly correlated with one another in all groups,
   including negative samples: VACV B5 with MPXV B6, VACV A33 with MPXV A35 and VACV
   A27 with MPXV A29, with the exception of MPXV A29 and VACV A27 in the negative samples.
- In negative samples, a number of antigens significantly correlated to one another including 309 310 MPXV A26 and MPXV A14, MPXV C19 and MPXV A33, MPXV D13 and MPXV A27, however all of the samples in this group demonstrated minimal antibody binding to these antigens 311 (Figure 3A, Supplementary Figure 4). However, within the Smallpox-vaccinated group 312 (IMVANEX or ACAM2000), a positive correlation was observed between a number of MPXV 313 antigens including B2 with A35, B6, E8 and M1, as well as VACV antigens A33 and B5 (Figure 314 **3B**). Similarly, in the MPOX convalescent group, MPXV antigen B2 correlated strongly with 315 MPXV antigens A35, B6, E8 and H3 but also with MPXV A27, and VACV antigens A27, A33 316 317 and B6 (Figure 3C).
- 318

# 319 Smallpox-vaccinated and MPOX-infected individuals mount a shared yet distinct 320 antibody-binding repertoire

Using antibody binding data of serum from individuals to the 24 MPXV and 3 VACV antigens, principal component analysis was performed to determine clusters in differential binding repertoires between pre-vaccination/negative individuals and that Smallpox vaccinated (Dose 1 IMVANEX, Dose 2 IMAVENEX and ACAM2000), or with prior MPOX infection groups (Clades IIa and Clade IIb).

326

327 Antibody binding within the negative group all clustered similarly close to one another, whilst dose 1 IMVANEX vaccinated individuals similarly clustered both with one another but also with 328 329 the negative samples (Figure 3D). Dose 2 IMVANEX vaccinated individuals showed distinct clusters, different from the negative samples, however, some of the IMAVNEX vaccinated 330 individuals clustered towards the negative samples (later time points post-two dose 331 332 vaccination, Supplementary Figure 4). MPOX convalescent individuals formed a distinct 333 grouping separately from IMVANEX vaccinated or negative samples, however, displayed a degree of overlap with both of these groups. ACAM2000 vaccinated individuals were not 334 335 distinctive, falling within the middle of the MPOX-convalescent samples but separate from the IMVANEX vaccinated samples (Figure 3D). 336

Using a biplot from the principal component analysis, individual antigens were highlighted as distinctive to particular groups (**Figure 3E**). For MPOX-infected individuals, MPXV antigen

A27 was the most specific to the MPOX-infected and ACAM2000 vaccinated group, followed

- by MPXV A14, D13 and A26, as well as VACV A27. Antigens specific to the IMVANEXvaccinated group were primarily MPXV M1, but also E8, A36 and VACV antigens B5 and A33.
- 343

# Using MPXV/VACV antigens as a differential for discriminating between MPOX and Smallpox vaccination

346

347 Based on a number of analyses (Figure 1, Figure 3D-E), several antigens show promise in being used to differentiate between Smallpox-vaccinated and MPOX-infected individuals. We 348 performed ROC analysis on some of the singular antigens identified in analyses described 349 here (MPXV A27 and MPXV M1) to determine their feasibility in discriminating between 350 vaccinated and infected (Figure 4, Table 3). No significant difference (p=0.8708) was 351 observed in antibody binding between the negative and IMVANEX vaccinated group for 352 353 antibodies binding MPXV A27, however, MPOX-infected individuals had significantly higher 354 antibody responses (p<0.0001) compared to negatives. Similarly, ACAM2000 individuals had 355 significantly (p<0.0001) higher antibodies to MPXV A27 than negatives (Figure 4A). Utilising the MPXV M1 antigen, only IMVANEX-vaccinated individuals had significantly higher 356 (p<0.0001) antibodies compared with the negative samples, ACAM2000 vaccinated, or 357 358 MPOX-infected individuals (Figure 4B).

359

# 360 Antigen exposure influences preferential binding to MPXV or VACV antigens

361

362 In our initial experiments, we observed that Smallpox-vaccinated and MPX-infected individuals 363 had similar binding to both the VACV B5 and the MPXV homologue B6 (Figure 1). Separating the Smallpox-vaccinated and the MPOX-infected groups, we observed preferential binding to 364 the protein that individuals were either vaccinated or infected with, whereby Smallpox-365 vaccinated individuals bind VACV B5 better than the MPXV homologue B6 and skewed 366 towards the B5 (VACV) axis (Figure 5A). Conversely, MPXV-infected individuals were found 367 368 to bind MPXV B6 better than the VACV homologue B5, with the majority of samples skewed 369 towards the B6 (MPXV) axis The same was also observed for the VACV-A33 and MPXV-A35 370 proteins(Figure 5B)., however, there was minimal antibody binding to either pox-virus antigen 371 observed in MVA-vaccinated individuals and only in MPOX-infected individuals. Homologues MPXV A29 and VACV A27 however demonstrated binding that was relatively limited to MPOX-372 infected individuals and skewed towards binding VACV A27 than MPXV A29 (Supplementary 373 374 Figure 5). MPOX-infected individuals aged ≥51 (and thus likely to have had prior-smallpox

- vaccination if UK born) did not show increased binding towards the VACV-antigen and were 375
- similar to the MPXV-infected individuals <51 (Supplementary Figure 6). 376

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



377

378 Figure 3: Correlation of antibody binding between MPXV/VACV antigens in A) MPOX convalescent and Smallpox-vaccinated individuals, B) Smallpox vaccinated individuals and 379 C) MPOX convalescent individuals. Coloured asterisks denote protein homologues between 380 MPXV and VACV. Significant p-values for each correlation can be found in Supplementary 381 figure 4. D) Principal component analysis of antibody binding to 23 MPXV and 3 VACV 382 recombinant antigens, plotted and coloured by group. Coloured circles represent all samples 383 within that cohort. E) Biplot of principal component analysis, highlighting that a number of 384 ELISAs using specific antigens can be used for each particular group. Note: C18L was 385 excluded from all correlation and principal component analysis due to non-specific antibody 386 binding. 387 388

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



390

Figure 4: Differential MPXV pox virus antigens used to determine A) Prior MPXV infection or ACAM2000 vaccination using MPXV A27, and B) recent IMVANEX vaccination using MPXV

392 ACA393 M1.



## 394

Figure 5: Differential binding to the A) VACV B5 and MPXV B6 and B) VACV A33 and
MPXV A35 proteins between the MPXV-infected individuals and MVA-vaccinated (IMVANEX
and ACAM2000) individuals. Those with MVA vaccination show stronger binding to the
VACV B5 and A33 protein compared to the MPXV B6 and A35 homologue, whilst MPXVinfected individuals show higher binding to the B6 and A35 protein. Contour lines represent
density of values.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# 401 Only a subset of MPXV and VACV antigens are recognised longitudinally following 402 IMVANEX vaccination, with waning observed

403

Using a time course from IMVANEX vaccinated individuals, we assessed the antibody binding 404 405 in these individuals; prior to vaccination, 28-days post-primary vaccination dose (post-dose 1 (PD1) D24), 14-days post second dose (PD2 D14), 43-days post-second dose (PD2 D43) and 406 407 63-days post second dose. The majority of individuals demonstrated no antibody binding to 408 the majority of antigens tested, demonstrated in earlier observations (Figure 1), however, 409 antibodies were able to bind nine antigens (MPXV antigens B6, B2, E8, A35, M1, A29 and 410 VACV antigens: B5 and A33) across the time course (Figure 6). Antibodies induced after one dose of vaccination were minimal, primarily to MPXV B2, however, an induction of antibodies 411 412 to all nine antigens was observed 14-days post-dose 2. Cross-reactive antibodies to MPXV C18 were observed across all time points. 413

414

415 Area under the curve (AUC) analysis identified nine antigens with a high AUC, with the 416 exception of A27, which was likely MPXV-specific (Table 3). Using Dunnett's multiple 417 comparison tests, we also identify a number of antigens that are significantly higher at the 418 different timepoints post-IMVANEX vaccination or MPOX-infection compared to negative 419 samples (Table 3). In particular, a number of MPXV antigens were significantly higher 14days post-dose 2 than negative samples (A29 (p=0.0043), A35 (p=<0.0001), E8 (p<0.0001) 420 and M1 (p = < 0.0001)) that showed no significant difference at day 63 post-dose 2. Similarly, 421 422 MPXV A27 and VACV A27 were not significantly different between negatives and post-423 vaccination, however, were significantly higher in MPOX-convalescent individuals compared with negatives (p< 0.0001). When comparing antigens overtime, we observed no significant 424 425 correlation in antibody binding to any of the antigens relative to time since infection (data not 426 shown).

427

Using individual antigens for detecting post-vaccination or post-MPOX-infection was assessed using ROC analysis (**Table 3**). We observed that individual antigens such as MPXV B2R, which had a sensitivity of 93.94% (95% CI: 80.39-98.92%) and specificity of 94.44% (95% CI: 74.24-99.72%) using a cut-off  $OD_{450nm}$  of >0.1743, were well suited in detecting postvaccination samples (both dose 1 and all time points for dose 2).

433

MPXV A27 was highly accurate in being able to discriminate MPXV-infected individuals, with
ROC analysis demonstrating 93.02% sensitivity (95% CI: 81.77% to 97.65%) and 94.44%
specificity (95% CI: 83.78% to 98.36%) using a cut-off OD<sub>450nm</sub> >0.1838 (**Table 3**). MPXV M1
gave a sensitivity of 72.73% (95% CI: 61.22% to 85.08%) and specificity of 94.44% (95% CI

438 74.24% to 99.72%) in detecting IMVANEX-vaccinated individuals using a cut-off of OD<sub>450nm</sub>
439 >0.07125.

440

# Antibodies from MPXV-infected and Smallpox-vaccinated individuals can reliably be detected using a pooled antigen ELISA

From the results of individual antigen testing, the dominant antigens recognised by MPXVinfected and Smallpox-vaccinated individuals (IMVANEX or ACAM2000) were highly similar: VACV antigens B5 and MPXV antigens A35, B2, B6 and E8. We sought to determine the feasibility in using a pool of these antigens as the basis of detecting pan-Poxvirus antibodies, preventing the requirement for use of whole-MVA/VACV or individual recombinant pox antigens. We explored the sensitivity and specificity of this pool and comparisons to individual antigen results.

450

Compared to individual antigens, higher ODs were obtained when samples were tested using 451 the pool antigen ELISA, compared with individual antigens, with trends in increasing antibody 452 453 titres following a second dose of vaccination, and waning observed 63 days post second dose 454 (Figure 6B). This sensitivity and specificity of this pooled antigen ELISA was then further 455 explored, to determine feasibility in detecting antibodies induced both by Smallpox vaccination and MPOX infection. An overall sensitivity of 97.14% (95% CI: 91.93% to 99.22%) and 456 457 specificity of 98.23% (95% CI: 96.67% to 99.07%) was determined using ROC analysis 458 (Figure 6C), with an OD cut off of 0.1926, based on testing the pooled antigen ELISA against 459 a total of 613 samples: 508 negatives (paediatric negatives, pre-vaccination samples and confounders) and 105 positives (IMVANEX vaccinated (Dose 1 or Dose 2), ACAM2000 460 vaccinated or MPOX infected (Clade IIa and IIb)). All samples tested positive by the pooled 461 antigen ELISA, with the exception of two MPOX-infected individuals, however these 462 463 individuals demonstrated no antibody binding to any of the MPXV/VACV antigens (Figure 1). AUC analysis identified the pool antigen ELISA as the highest AUC compared to any individual 464 465 antigen but was also the only ELISA that show significantly higher results in post-dose 1 vaccinated individuals compared to negative samples, further demonstrating the utility of this 466 467 pooled antigen ELISA (Table 3). This assay could be further quantified by performing endpoint 468 titres, serially diluting samples 1:4 until the cut off of 0.1926 was achieved (Figure 6D, Table 469 3).

470

When using a combined antigen pool, this resulted in a potentiation of antibodies detected by
ELISA (Lower panel, Figure 1). In general, all samples tested on the individual antigens had
lower antibodies determined by OD measurement than the pooled antigen ELISA (Figure 6E),
with linear regression models similarly demonstrating higher ODs in the pooled antigen ELISA

475 relative to the individual antigens (Figure 6F). When comparing ROC analysis, the highest sensitivity and specificity for detecting antibodies induced by Smallpox vaccination or MPOX-476 infection was in fact the pooled antigen ELISA, with 98.31% and 95.65% sensitivity, and 477 478 98.23% and 98.03% specificity, respectively (Table 3).

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



480

481

Figure 6: Longitudinal sampling of individuals receiving IMAVENEX vaccination against A) a 482 483 panel of 24 MPXV and 3 VACV antigens or B) Pooled antigen ELISA. C) Evaluation of the pooled antigen ELISA to determine sensitivity and specificity. D) Using the pooled antigen 484 ELISA, endpoint titres were determined for positive groups. Comparison of the ELISA results 485 of MPXV-infected and Smallpox-vaccinated serum samples using individual antigens relative 486 to the pool of antigens E) split by antigen, or F) linear regression of individual antigen results 487 relative to pooled antigen ELISA results. Dotted lines represent the 95% confidence intervals. 488 Black lines represent X=Y. 489

490 **Table 3:** Statistical analysis of individual MPXV/VACV antigens in detecting Smallpox- or MPXV-specific antibody responses. Area under the curve analysis

491 was performed using longitudinal IMVANEX samples. Dunnett's multiple comparisons test were used for each group, relative to the negative control samples.

492 ROC-analysis was used to determine sensitivity and specificity of antigens in detecting antibodies induced by either Smallpox vaccination of MPOX-infection. \*

493 - non-specific binding was observed to C18. Those antigens listed in bold had at least one significant difference relative to the negative samples.

		Area Under the Curve (IMVANEX)		Dunnett's Multiple Comparisons Test (versus				ROC Analysis (versus Pre-IMVANEX)							
Virus	Protein	7.100				r	negatives)				Smallpox Vacci	ne	N	IPOX Convales	cent
		Total Area	Std. Error	95% Confidence Interval	PD1 D24	PD2 D14	PD2 D43	PD2 D63	MPX ≥2022	Cut-off	Sensitivity (%)	Specificity (%)	Cut-off	Sensitivity (%)	Specificity (%)
	A5	0.3077	0.1728	0.000 to 0.646	ns	ns	ns	ns	ns	< 0.0417	66.67	61.11	> 0.2103	30.23	88.89
	A14	0.1477	0.06122	0.027 to 0.268	ns	ns	ns	ns	ns	< 0.0641	87.88	38.89	> 0.0699	58.14	77.78
	A26	0.05971	0.04553	0.000 to 0.149	ns	ns	ns	ns	ns	< 0.0010	63.64	55.56	> 0.1233	16.28	94.44
	A27	0.3266	0.3174	0.000 to 0.949	ns	ns	ns	ns	****	> 0.0527	33.33	77.78	> 0.1838	93.02	94.44
	A29	0.5752	0.714	0.000 to 1.975	ns	**	ns	ns	***	> 0.0438	27.27	94.44	> 0.0441	86.05	94.44
	A33	0.1653	0.04762	0.0712 to 0.259	ns	ns	ns	ns	ns	> 0.0809	24.24	94.44	> 0.0783	34.88	94.44
	A35	1.696	0.4814	0.752 to 2.639	ns	****	*	ns	****	> 0.0661	63.64	94.44	> 0.0661	95.35	94.44
	A36	0.7491	0.2666	0.227 to 1.272	ns	ns	ns	ns	ns	> 0.1685	42.42	77.78	< 0.0025	25.58	94.44
	A44	0.3298	0.3876	0.000 to 1.089	ns	ns	ns	ns	ns	> 0.0007	63.64	61.11	> 0.1228	23.26	94.44
	B2	3.446	0.4966	2.473 to 4.420	ns	****	****	***	****	> 0.1743	93.94	94.44	> 0.2002	93.02	94.44
	B5	1.018	0.6515	0.000 to 2.295	ns	ns	ns	ns	ns	< 0.1375	39.39	83.33	< 0.1010	41.86	88.89
	B6	3.98	1.119	1.787 to 6.172	ns	****	****	****	****	> 0.0516	87.88	94.44	> 0.0186	97.67	94.44
	C15	0.173	0.0447	0.085 to 0.261	ns	ns	ns	ns	ns	< 0.0130	24.24	94.12	< 0.0123	41.46	94.12
	C18*	2.573	0.3455	1.896 to 3.250	ns	ns	ns	ns	ns	> 0.8333	33.33	94.12	> 0.8421	39.02	94.12
	C19	0.08756	0.03286	0.023 to 0.152	ns	ns	ns	ns	ns	> 0.0448	30.3	94.44	> 0.0438	27.91	94.44
	D13	0.1751	0.0693	0.039 to 0.311	ns	ns	ns	ns	ns	> 0.0471	45.45	72.22	> 0.1163	37.21	88.89
	D14	0.08473	0.03667	0.013 to 0.157	ns	ns	ns	ns	ns	< 0.0059	57.58	77.78	< 0.0066	60.47	77.78
	E8	2.326	0.6156	1.120 to 3.533	ns	****	****	ns	***	> 0.1319	69.7	94.44	> 0.1257	88.37	94.44
	F3	0.1377	0.04353	0.052 to 0.223	ns	ns	ns	ns	ns	< 0.0296	54.55	58.82	> 0.0713	29.27	94.12
	H3	0.3635	0.3254	0.000 to 1.001	ns	ns	ns	ns	ns	> 0.0346	45.45	83.33	> 0.1922	51.16	94.44
	l1	0.000525	0.001485	0.000 to 0.003	ns	ns	ns	ns	ns	> 0.0042	3.03	100	> 0.0052	30.95	100
	L1	0.07473	0.04909	0.000 to 0.171	ns	ns	ns	ns	ns	> 0.0248	18.18	94.44	> 0.0231	34.88	94.44
	L4	0.2374	0.1457	0.000 to 0.5230	ns	ns	ns	ns	ns	> 0.1103	15.15	94.44	< 0.0027	48.84	66.67
	M1	1.57	0.549	0.4943 to 2.646	ns	****	**	ns	ns	> 0.0254	72.73	94.44	> 0.0249	47.62	94.44
	A27	0.588	0.354	0.000 to 1.282	ns	ns	ns	ns	****	< 0.0116	21.21	94.12	> 0.3892	83.72	94.12
VACV	A33	3.067	0.6535	1.786 to 4.348	ns	****	****	*	****	> 0.2249	72.73	94.12	> 0.1387	83.72	94.12
	B5	4.927	1.135	2.702 to 7.152	ns	****	****	****	****	> 0.1657	84.85	94.44	> 0.2354	74.42	94.44
Pooled a	ntigen ELISA	6.968	0.8284	5.345 to 8.592	*	****	****	****	****	> 0.1926	98.31	98.23	> 0.1535	95.65	98.03

#### 495 Discussion

## 496

497 MPXV was detected in a wide range of countries during the 2022 outbreak after the initial identification of cases within the UK. Vaccination strategies have been implemented through 498 a number of public health agencies worldwide as means to limit the spread of the disease and 499 protect individuals from infection. Here, we have demonstrated that antibody responses 500 induced by two widely used and licensed Smallpox vaccines (IMVANEX and ACAM2000, post-501 dose 1, 2 and 3) and prior MPOX infection (both prior Clade IIa or the current 2022 Clade IIb 502 503 outbreak) are similar and are able to bind a number of MPXV and VACV antigens. We also 504 describe the development of a pooled antigen ELISA to study both Smallpox-vaccine and 505 MPOX-infection antibody responses.

506

### 507 Analogous antigen recognition is observed between Smallpox-vaccinated and 508 Monkeypox-convalescent individuals

Using an array of 27 different pox-virus antigens (24 MPXV and 3 VACV), we observe that 509 Smallpox-vaccination (be it IMVANEX or ACAM2000) induces a similar antibody response to 510 those previously infected with MPOX, both Clades IIa and IIb. Minimal antibodies to the 511 diverse pox-virus antigens were observed in negative samples, with all negative samples 512 correlating positively to one another (Figure 1, Figure 2). Surprisingly, however, those with 513 514 one dose of IMVANEX vaccination demonstrated minimal antigen binding, such as with 515 negative samples, except for the presence of some antibodies able to bind MPXV B2 in onedose vaccinated individuals, likely explaining the minimal and variable correlation observed in 516 this group to other vaccinated or MPOX-infected groups (Figure 2). However, variations in 517 Eukaryotic/Prokaryotic-expressed proteins also need to be further assessed to determine 518 519 effects due to glycosylation. Furthermore, differences in delivery (subcutaneous vs 520 intradermal) and dosing (full versus fractional dosage) of the IMVANEX vaccination may play 521 additional roles in induction of antibody and antigen binding, which was not studied here and 522 warrants further investigation.

523

Nevertheless, a lack of robust antibody responses after one dose of IMVANEX in previously 524 525 unvaccinated individuals (aged <50) does not suggest a lack of protection, as recent studies have shown that vaccine efficacy against disease after one dose of IMVANEX has been 526 suggested to be as high as 78% when comparing vaccinated with unvaccinated individuals<sup>45</sup>. 527 However, one vaccination dose has been shown to induce low-neutralising antibodies<sup>46</sup>, likely 528 529 suggesting a role of cellular or T-cell immunity not measured in this study but performed by others<sup>37–39</sup>. 530

# 531

532 Within our study, we demonstrate that a number of antibodies capable of binding diverse pox-533 virus antigens are induced by two-dose IMVANEX-vaccination or MPOX prior infection (Clade 534 Ila and Clade IIb), with high correlation between individuals in these groups and to one another 535 (**Figure 2**). Even though we only have three Clade IIa convalescent samples, we observe no 536 difference in antigen recognition between a Clade IIa and IIb MPOX infection, which should 537 be further explored to understand the role of mutations in Clade IIb and their possible role in 538 transcriptional changes and hence antigen recognition after MPOX infection<sup>25,26</sup>.

539

However, whilst there is a high correlation between antibody binding to diverse MPXV/VACV 540 antigens in two-dose IMVANEX-vaccinated and MPOX-infected individuals, distinctive but 541 542 overlapping grouping are observed when performing principal component analysis (Figure 543 **3D**) which is further narrowed with post-vaccination antibody waning (Supplementary Figure 4). These data suggest a core set of antigens shared across repeated IMVANEX vaccination 544 and a MPOX infection and similarity across viral epitopes by both the MVA-BN virus used in 545 the IMVANEX vaccine and an MPXV infection<sup>37</sup>. This aligns with the observed protection 546 547 afforded when MVA was used for vaccination against MPXV infection in macagues<sup>28,29</sup> or used 548 in regions with high MPXV prevalence<sup>5</sup>. Prior studies have demonstrated a difference in 549 neutralising titres between those infected with MPOX aged <48 and >48<sup>46</sup>, however, we see no discernible difference in antibody binding to all MPXV and VACV antigens measured in this 550 study (Supplementary Fig 1) but similarly confirm the low level of IgG induced by single 551 IMVANEX vaccination. When performing principal component analysis, antibody waning in 552 553 two-dose IMVANEX-vaccinated individuals results in the harmonisation of IMVANEX preventing 554 vaccinated with MPOX-infected groups, discrimination (Figure 3D. Supplementary Figure 4). This suggests that other additional assays will be required for 555 differentiating between MPOX-infected and VACV-vaccinated individuals such as specific-556 557 antigens or an avidity assay.

558

Immunological signatures for MPOX infection were identified such as antibodies induced to 559 the MPXV A27 protein (Figure 3C, Figure 4E and Table 2-3), a cowpox-like type A inclusion 560 561 protein that is present in the strain used in the ACAM2000 vaccination and MPXV isolates but 562 missing in MVA-BN (IMVANEX) and VACV Copenhagen. The absence of A27 in VACV Copenhagen and MVA-BN may provide the ability of MPXV A27 to be used as a differential 563 564 assay in serosurveillance studies in countries such as the UK, that do not or have not previously used the ACAM2000 smallpox vaccine. However, further work is required to ensure 565 that cross-reactivity of antibodies to MPXV A27 is not observed in those with other 566 Chordopoxvirinae infections and that a MPXV A27 assay can be used to also detect prior 567

568 infection with MPXV Clade I that was not assessed here. Similarly, we also identify MPXV M1 569 (VACV homologue L1) as a serological marker of IMVANEX-vaccination (Figure 5B), but antibodies able to bind M1 were observed in some MPOX-infected individuals, possibly due 570 to prior Smallpox-vaccination. The reasoning for MPXV M1 (VACV L1); an IMV surface 571 membrane protein that has shown to be protective against poxvirus challenge<sup>47-49</sup>, as a 572 differential between IMVANEX vaccinated and MPOX-infected or ACAM2000 vaccinated is 573 unknown, and warrants further investigation, as it is present in all VACV and MPXV strains, 574 with >98% amino acid identity between VACV Copenhagen and MPXV Zaire. 575

576

577 Similarly, whilst individual antigens show distinct and differential binding, binding between 578 VACV and MPXV homologous antigens is different depending on individuals having VACV 579 vaccination or an MPXV infection (**Figure 5**). This is further supported by recent work that 580 demonstrated Smallpox-vaccine naïve individuals (e.g. aged <48) neutralise MPXV better 581 than VACV<sup>46</sup>, reinforcing a virus-specific immunological response that should be further 582 explored in those with heterologous antigenic exposures.

583

We also observe a waning in antibodies at day 84 post two doses, with a decrease in 584 antibodies able to bind the diverse antigens observed at 14 days post two doses and endpoint 585 titres using a pooled antigen ELISA (Figure 2, Figure 6). The further extent of this antibody 586 and antigen-specific waning is to be explored, as others have demonstrated waning to 587 individual antigens<sup>50</sup>, whilst persistence of IgG and neutralising antibodies up to 88 years post-588 589 vaccination have been observed<sup>51</sup>. Further work is needed to study the immunogenicity and persistence of antibodies to diverse pox-virus antigens after MPOX infection and/or IMVANEX 590 591 vaccination, as means to provide data on antibody persistence and inform recommendations 592 for future vaccination boosters in communities at-risk of MPOX transmission or infection. We 593 are now also pursuing an understanding of the immunological impact of heterologous (both 594 full and partial dosage) antigen exposure in those with MPOX infection followed by two IMVANEX doses, to understand antibody persistence and repertoire. 595

596

597 The presence of antibodies able to bind MPXV C18 (VACV F12), an IEV actin tail formation 598 protein<sup>52</sup>, across all samples suggests either cross-reactivity of antibodies to the recombinant 599 antigen or non-specific sequestration of immunoglobulins. Further work is ongoing to 600 understand antibody binding and MPXV C18.

601

602 A pooled MPXV and VACV antigen ELISA is sensitive and specific than individual 603 antigens

605 To perform reliable immunological studies on Smallpox vaccination, MPOX infection or 606 serosurveillance, standardised and highly congruous ELISA assays are needed. Whilst a 607 number of pox virus ELISAs use whole-MVA or inactivated VACV, this method requires virus growth and quality control with batch-to-batch variability. Using the data from our antigen 608 609 panels, we describe the development of a pooled-antigen ELISA using commercially available recombinant antigens to study Smallpox-vaccine- and MPXV-induced antibody response. 610

611

Using a number of pre-vaccination/negative samples, longitudinal samples from IMVANEX 612 613 vaccinated individuals, those with prior ACAM2000 vaccination but also MPOX-infected 614 individuals, we demonstrate the use of nine antigens in detecting antibody responses in each of these groups (Table 3, MPXV antigens B6, B2, E8, A35, M1, A29 and VACV antigens: B5 615 and A33). Whilst some of these antigens are highly sensitive and specific to detecting 616 617 Smallpox-vaccination- or MPOX-infection-induced antibodies, the highest achieved was a pool of five antigens (MPXV B2, B6, E8, A35 and VACV B5). This pooled antigen assay 618 619 demonstrates high sensitivity and specificity but also potentiation in antibodies detected than singular antigen ELISAs (Figure 1, Figure 6E-F). Furthermore, quantitation through endpoint 620 621 titres is possible and enables quantification of antibody responses following vaccination and 622 MPOX infection (Figure 6D).

623

The high sensitivity and specificity of the pool are explained by the recombinant antigen 624 components: MPXV B2 (VACV homologue A56) is an EEV Type I membrane glycoprotein 625 hemagglutinin that is integral for in vivo and in vitro spread of VACV, as well as binding 626 additional VACV proteins in infected cell membranes<sup>53–55</sup>. MPXV E8 (VACV homologue D8) 627 is an IMV surface membrane protein, shown to be involved in virus entry through binding 628 chondroitin sulphate, eliciting strong humoral immunity<sup>56,57</sup>. MPXV B6 (and VACV homologue 629 B5) is a 42-kDa EEV outer surface antigen, previously shown to be a major target of EEV-630 neutralising antibodies<sup>47,58,59</sup>, likely explaining the immunogenicity observed to MPXV B6 and 631 VACV B5 in this study. Similarly, MPXV A35 (VACV homologue A33) is an EEV envelope 632 protein and also a source of EEV protective antibodies<sup>47,58</sup>, whilst also previously 633 demonstrated to be associated with B5<sup>60</sup>. Previous studies have also demonstrated anti-A33 634 (MPXV A35) and anti-B5 (MPXV B6) monoclonal antibodies (mAbs) as protective against 635 lethal VACV-challenge in mice<sup>61,62</sup>, however combinations of anti-VACV mAbs afforded the 636 highest protection. These proteins are highly conserved between VACV and MPXV<sup>49</sup> (Table 637 638 2), likely suggesting minimal changes in assay sensitivity if VACV homologues were used, however, based on differential binding demonstrated here (Figure 4, Supplementary Figure 639 5 and 6), this should be further explored. 640

642 As a number of antibodies are induced to these antigens due to MPOX-infection, further work 643 is warranted to determine if a combination of these antigens provide protection from disease 644 as next-generation Smallpox vaccines. Prior work has similarly demonstrated that some of these antigens (both individually or combined) induce a robust antibody response when used 645 in an mRNA<sup>63,64</sup> or DNA<sup>47-49</sup> vaccine, some of which have demonstrated protection against 646 disease. Similarly, monoclonal antibodies against some of these antigens may provide new 647 post-exposure or long-lasting therapeutics for MPOX or broad poxvirus disease, in 648 replacement of convalescent serum such as VIG or recombinant VIG<sup>61,62,65</sup>. 649

650

# 651 Strengths and weaknesses of this study

652

One of the major strengths of this study is that we used a large number of whole recombinant 653 MPXV/VACV antigens, some of which are produced in mammalian cells, which are more 654 representative of viral proteins (including glycosylation) than linear peptides used in protein 655 arrays. Furthermore, using 24 MPXV antigens, this covers ~15% of proteins encoded within 656 657 the MPXV genome. Further work is now ongoing to perform expression and purification of all 658 MPXV antigens to determine the range of antibodies involved in antigen binding induced by 659 infection/vaccination using customised-multiplex assays (e.g., Luminex) to determine binding 660 to whole proteins rather than linear epitopes using protein microarrays. Additional VACV homologues are also being sought to provide additional information on the preferential 661 binding. 662

663

664 Our pooled antigens are skewed towards MPXV, though the data demonstrated here show 665 that this pool is the only assay (compared to individual antigens) capable of detecting a 666 statistically significant increase in antibodies relative to negative controls. Further optimisation 667 of this antigen pool is ongoing to determine optimum antigens for use in vaccination 668 immunology studies and serosurveillance.

669

570 Similarly, we did not conduct MVA, VACV or MPXV neutralisation as part of this study, 571 however, our observations of low antibodies induced post one-dose of IMAVENX correlates 572 to observations by others<sup>46</sup>. Further work is needed to understand the role of binding and 573 neutralising antibodies in the context of correlates of protection.

674

Finally, the samples we used within this study were a diverse mix of vaccination/MPOX samples from individuals at differing time points, however further time points are required to monitor waning in both the vaccination and MPOX-vaccinated individuals, as well as assessing antibody persistence in those with heterologous antigenic exposure.

### 679 Conclusions

# 680

681 Here, our results provide a wealth of information on the immunology of MPOX infection, but 682 also demonstrate analogous humoral antigen binding between those with Smallpoxvaccination (IMVANEX or ACAM2000) and those with prior MPOX infection (both Clade IIa 683 and IIb). Furthermore, the singular proteins identified in this study in the immunological 684 responses to both Smallpox vaccination and MPOX-infection may offer new targets for future 685 vaccination strategies (e.g., mRNA vaccines) or therapeutics (e.g., mAbs). Similarly, using the 686 analogous immune responses between Smallpox-vaccinated and MPOX-convalescent, we 687 developed a highly sensitive and specific pooled antigen ELISA that offers a mechanism for 688 reliably measuring immune responses post-infection or post-vaccination without the need for 689 whole-virus ELISAs or live-virus neutralisation. These together offer an opportunity for the 690 691 development and assessment of next-generation vaccinations.

# 693 **Funding**

This work was funded by the UK Health Security Agency, with additional funding obtained from the Coalition for Epidemic Preparedness Initiative (CEPI) for the development of a MPOX/Smallpox ELISA assay.

697

# 698 Acknowledgements

We would like to thank members of the CEPI, in particular Valentina Bernasconi, Mark Manak
and Ali Azizi for their guidance throughout the development of the pooled antigen ELISA
assay. We also are thankful to members of the Chelsea and Westminster and Imperial College
Healthcare trusts that helped in obtaining MPOX-convalescent serum.

### 705 References

- 1. Lansiaux, E., Jain, N., Laivacuma, S. & Reinis, A. The virology of human monkeypox 706 virus (hMPXV): A brief overview. Virus Res. 322, (2022). 707
- 2. Dabrowski, P. W., Radonić, A., Kurth, A. & Nitsche, A. Genome-wide comparison of 708 709 cowpox viruses reveals a new clade related to variola virus. PLoS One 8, 79953 (2013). 710
- 711 3. Shchelkunov, S. N. Emergence and reemergence of smallpox: The need for 712 development of a new generation smallpox vaccine. Vaccine 29, D49–D53 (2011).
- 4. Malshetty, V. S., Jain, R., Srinath, T., Kurthkoti, K. & Varshney, U. Synergistic effects 713 714 of UdgB and Ung in mutation prevention and protection against commonly encountered DNA damaging agents in Mycobacterium smegmatis. *Microbiology* **156**, 715 716 940-949 (2010).
- Priyamvada, L. & Satheshkumar, P. S. Variola and Monkeypox Viruses (Poxviridae). 717 5. Encycl. Virol. 2, 868-874 (2021). 718
- 719 6. Strassburg, M. A. The global eradication of smallpox. AJIC Am. J. Infect. Control 10, 720 53-59 (1982).
- Smith, K. A. Edward Jenner and the small pox vaccine. Frontiers in Immunology 2, 21 721 7. 722 (2011).
- 8. Goebel, S. J. et al. The complete DNA sequence of vaccinia virus. Virology 179, 247-723 266 (1990). 724
- 725 9. Lewis, F. M. T. et al. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg. Infect. Dis. 12, 134–137 (2006). 726
- Silva-Fernandes, A. T. et al. Natural human infections with Vaccinia virus during 727 10. bovine vaccinia outbreaks. J. Clin. Virol. 44, 308-313 (2009). 728
- 11. Pennington, H. Smallpox and bioterrorism. Bulletin of the World Health Organization 729 81, 762–767 (2003). 730
- 12. Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. 731 (2003). doi:10.1038/nm917 732
- Weaver, J. R. & Isaacs, S. N. Monkeypox virus and insights into its 733 13. 734 immunomodulatory proteins. Immunological Reviews 225, 96-113 (2008).
- 14. Wilson, M. E., Hughes, J. M., McCollum, A. M. & Damon, I. K. Human monkeypox. 735 736 Clin. Infect. Dis. 58, 260-267 (2014).
- Vaughan, A. et al. Two cases of monkeypox imported to the United Kingdom, 737 15. september 2018. Eurosurveillance 23, 1800509 (2018). 738
- 16. Vaughan, A. et al. Human-to-human transmission of monkeypox virus, United 739 Kingdom, October 2018. Emerg. Infect. Dis. 26, 782-785 (2020). 740
- 741 17. Hobson, G. et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Eurosurveillance 26, 2100745 (2021). 742
- 743 18. Karem, K. L. et al. Characterization of acute-phase humoral immunity to monkeypox: Use of immunoglobulin m enzyme-linked immunosorbent assay for detection of 744 745 monkeypox infection during the 2003 north American outbreak. Clin. Diagn. Lab. 746 Immunol. 12, 867–872 (2005).
- 747 19. Stephenson, J. Monkeypox Outbreak a Reminder of Emerging Infections

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

748 Vulnerabilities. JAMA 290, 23-24 (2003). 20. Reynolds, M. G. et al. Spectrum of infection and risk factors for human monkeypox, 749 750 United States, 2003. Emerg. Infect. Dis. 13, 1332–1339 (2007). European Centre for Disease Prevention and Control. Epidemiological update: 751 21. 752 Monkeypox multi-country outbreak. (2022). Available at: 753 https://www.ecdc.europa.eu/en/news-events/epidemiological-update-monkeypoxmulti-country-outbreak. (Accessed: 14th December 2022) 754 755 22. UK Health Security Agency. Monkeypox outbreak: epidemiological overview, 4 October 2022 - GOV.UK. (2022). Available at: 756 757 https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-758 overview/monkeypox-outbreak-epidemiological-overview-4-october-2022. (Accessed: 759 14th December 2022) 760 23. Mathieu, E., Spooner, F., Dattani, S., Ritchie, H. & Roser, M. Mpox (monkeypox). Our 761 World in Data (2022). Available at: https://ourworldindata.org/monkeypox. (Accessed: 17th December 2022) 762 763 24. Wang, L. et al. Genomic annotation and molecular evolution of monkeypox virus 764 outbreak in 2022. J. Med. Virol. 95, e28036 (2022). 25. 765 Gigante, C. M. et al. Multiple lineages of monkeypox virus detected in the United 766 States, 2021–2022. Science (80-. ). 378, 560–565 (2022). 26. Isidro, J. et al. Phylogenomic characterization and signs of microevolution in the 2022 767 multi-country outbreak of monkeypox virus. Nat. Med. 28, 1569–1572 (2022). 768 769 27. Townsend, M. B. et al. Humoral Immunity to Smallpox Vaccines and Monkeypox Virus 770 Challenge: Proteomic Assessment and Clinical Correlations. J. Virol. 87, 900–911 (2013). 771 772 28. Nigam, P. et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366, 773 774 73-83 (2007). 29. Edghill-Smith, Y. et al. Smallpox vaccine-induced antibodies are necessary and 775 sufficient for protection against monkeypox virus. Nat. Med. 11, 740-747 (2005). 776 777 30. Earl, P. L. et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. (2004). 778 31. Stittelaar, K. J. et al. Modified Vaccinia Virus Ankara Protects Macagues against 779 Respiratory Challenge with Monkeypox Virus. J. Virol. 79, 7845–7851 (2005). 780 781 32. Townsend, M. B. et al. Retrospective Proteomic Analysis of Serum After Akhmeta 782 Virus Infection: New Suspect Case Identification and Insights Into Poxvirus Humoral 783 Immunity. J. Infect. Dis. 216, 1505–1512 (2017). 784 33. Keasey, S. et al. Proteomic basis of the antibody response to monkeypox virus infection examined in cynomolgus macaques and a comparison to human smallpox 785 786 vaccination. PLoS One 5, (2010). Gallwitz, S., Schutzbank, T., Heberling, R. L., Kalter, S. S. & Galpin, J. E. Smallpox: 34. 787 788 Residual antibody after vaccination. J. Clin. Microbiol. 41, 4068–4070 (2003). Earl, P. L. et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and 789 35. 790 protection against monkeypox. Nature 428, 182-185 (2004). 791 36. Davies, D. H. et al. Proteome-wide analysis of the serological response to vaccinia

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- and smallpox. *Proteomics* **7**, 1678–1686 (2007).
- 37. Grifoni, A. *et al.* Defining antigen targets to dissect vaccinia virus (VACV) and
   Monkeypox virus (MPXV)-specific T cell responses in humans. *Cell Host Microbe* 1662–1674 (2022). doi:10.1016/j.chom.2022.11.003
- Agrati, C. *et al.* Immunological signature in human cases of monkeypox infection in
  2022 outbreak: an observational study. *Lancet Infect. Dis.* **3099**, 1–11 (2022).
- 39. Karem, K. L. *et al.* Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. *Clin. Vaccine Immunol.* 14, 1318–1327 (2007).
- 40. Shchelkunov, S. N. *et al.* Analysis of the monkeypox virus genome. *Virology* 297, 172–194 (2002).
- Brown, E., Senkevich, T. G. & Moss, B. Vaccinia Virus F9 Virion Membrane Protein Is
  Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein. *J. Virol.* 80, 9455–9464 (2006).
- 42. Chiu, W.-L. & Chang, W. Vaccinia Virus J1R Protein: a Viral Membrane Protein That Is Essential for Virion Morphogenesis. *J. Virol.* **76**, 9575–9587 (2002).
- 43. Ember, S. W. J., Ren, H., Ferguson, B. J. & Smith, G. L. Vaccinia virus protein C4
  inhibits NF-κB activation and promotes virus virulence. *J. Gen. Virol.* 93, 2098–2108
  (2012).
- 44. Patel, D. D., Pickup, D. J. & Joklik, W. K. Isolation of cowpox virus a-type inclusions
  and characterization of their major protein component. *Virology* 149, 174–189 (1986).
- 813 45. Bertran, M. *et al.* Effectiveness of one dose of MVA-BN smallpox vaccine against
  814 monkeypox in England using the case-coverage method. *UK Heal. Secur. Agency*815 (2022).
- 46. Zaeck, L. M. *et al.* Low levels of monkeypox virus-neutralizing antibodies after MVABN vaccination in healthy individuals. *Nat. Med.* (2022). doi:10.1038/s41591-02202090-w
- 47. Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. DNA vaccination
  with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus
  challenge. *Virology* 266, 329–339 (2000).
- 48. Hooper, J. W. *et al.* Smallpox DNA Vaccine Protects Nonhuman Primates against
  Lethal Monkeypox. *J. Virol.* 78, 4433–4443 (2004).
- 49. Hooper, J. W., Custer, D. M. & Thompson, E. Four-gene-combination DNA vaccine
  protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody
  responses in nonhuman primates. *Virology* **306**, 181–195 (2003).
- Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. Quantification of antibody
  responses against multiple antigens of the two infectious forms of Vaccinia virus
  provides a benchmark for smallpox vaccination. *Nat. Med.* 12, 1310–1315 (2006).
- Taub, D. D. *et al.* Immunity from Smallpox Vaccine Persists for Decades: A
  Longitudinal Study. *Am. J. Med.* **121**, 1058–1064 (2008).
- S2. Zhang, W.-H., Wilcock, D. & Smith, G. L. Vaccinia Virus F12L Protein Is Required for
  Actin Tail Formation, Normal Plaque Size, and Virulence. *J. Virol.* 74, 11654–11662
  (2000).
- 53. Girgis, N. M. et al. Cell Surface Expression of the Vaccinia Virus Complement Control

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283648; this version posted December 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

- 836 Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected 837 Cells from Complement Attack. *J. Virol.* **82**, (2008).
- 838 54. Wagenaar, T. R. & Moss, B. Expression of the A56 and K2 Proteins Is Sufficient To 839 Inhibit Vaccinia Virus Entry and Cell Fusion. *J. Virol.* **83**, 1546–1554 (2009).
- de Haven, B. C., Gupta, K. & Isaacs, S. N. The vaccinia virus A56 protein: A
  multifunctional transmembrane glycoprotein that anchors two secreted viral proteins. *Journal of General Virology* 92, 1971–1980 (2011).
- 843 56. Berhanu, A. *et al.* Vaccination of BALB/c Mice with Escherichia coli -Expressed
  844 Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus
  845 Challenge . *J. Virol.* 82, 3517–3529 (2008).
- 57. Demkowicz, W. E., Maa, J. S. & Esteban, M. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. *J. Virol.* **66**, 386–398 (1992).
- 58. Bell, E. *et al.* Antibodies against the extracellular enveloped virus B5R protein are
  mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. *Virology* 325, 425–431 (2004).
- 852 59. Nakatake, M. *et al.* Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus
  853 Neutralization Escape while Preserving Oncolytic Function. *Mol. Ther. Oncolytics* 14, 159–171 (2019).
- 60. Perdiguero, B. & Blasco, R. Interaction between Vaccinia Virus Extracellular Virus Envelope A33 and B5 Glycoproteins. *J. Virol.* **80**, 8763–8777 (2006).
- 61. Gilchuk, I. *et al.* Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. *Cell* **167**, 684-694.e9 (2016).
- 62. Chen, Z. *et al.* Characterization of Chimpanzee/Human Monoclonal Antibodies to
  Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a
  Vaccinia Virus Mouse Protection Model. *J. Virol.* **81**, 8989–8995 (2007).
- 862 63. Sang, Y. *et al.* Monkeypox virus quadrivalent mRNA vaccine induces antibody
  863 responses and cellular immunity and protects mice against Vaccinia virus. *bioRxiv*864 2022.11.22.517500 (2022). doi:10.1101/2022.11.22.517500
- 865 64. Mucker, E. M. *et al.* A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the
  866 Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal
  867 Rabbitpox Virus Aerosol Challenge. *J. Virol.* **96**, (2022).
- 868 65. Bloch, E. M. *et al.* The Potential Role of Passive Antibody-Based Therapies as
  869 Treatments for Monkeypox. *MBio* (2022). doi:10.1128/mbio.02862-22
- 870